losartan has been researched along with Coronary Restenosis in 5 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In Study 2, 44 patients with acute myocardial infarction who randomly received an initial lower dose of either valsartan or losartan after stenting were evaluated." | 9.12 | Do valsartan and losartan have the same effects in the treatment of coronary artery disease? ( Imaizumi, S; Iwata, A; Kiya, Y; Kumagai, K; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Shirai, K; Zhang, B, 2007) |
| " In Study 2, 44 patients with acute myocardial infarction who randomly received an initial lower dose of either valsartan or losartan after stenting were evaluated." | 5.12 | Do valsartan and losartan have the same effects in the treatment of coronary artery disease? ( Imaizumi, S; Iwata, A; Kiya, Y; Kumagai, K; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Shirai, K; Zhang, B, 2007) |
| " The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction." | 4.82 | [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sato, H | 1 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Okigaki, M | 1 |
| Iwasaka, T | 1 |
| Xu, G | 1 |
| Li, XS | 1 |
| Huang, WQ | 1 |
| Huang, H | 1 |
| Iwata, A | 1 |
| Miura, S | 1 |
| Imaizumi, S | 1 |
| Kiya, Y | 1 |
| Nishikawa, H | 1 |
| Zhang, B | 1 |
| Shimomura, H | 1 |
| Kumagai, K | 1 |
| Matsuo, K | 1 |
| Shirai, K | 1 |
| Saku, K | 1 |
3 reviews available for losartan and Coronary Restenosis
| Article | Year |
|---|---|
[Acute myocardial infarction].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Tria | 2002 |
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An | 2003 |
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].
Topics: Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2004 |
1 trial available for losartan and Coronary Restenosis
| Article | Year |
|---|---|
Do valsartan and losartan have the same effects in the treatment of coronary artery disease?
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Case-Control Studies; Coronary Angiography; Coronary | 2007 |
1 other study available for losartan and Coronary Restenosis
| Article | Year |
|---|---|
[Effect of probucol and losartan on growth factors after balloon angioplasty in rabbits].
Topics: Angioplasty, Balloon; Animals; Anticholesteremic Agents; Coronary Restenosis; Drug Therapy, Combinat | 2006 |